IP Library › Patent Application 14324520
Patent Application
App. No. 14/324,520

HUMAN ANTIBODIES AND PROTEINS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/324,520
Abstract

The present invention provides composite proteins, including antibodies, which show reduced immunogenicity. In particular, composite antibodies for use in humans are provided, in particular antibodies which have been modified to remove one or more T-cell epitopes. Methods for generating such proteins are also provided.

Claims (31)

1 . A modified antibody or antigen-binding fragment thereof wherein the heavy and light chain variable regions of the modified antibody or antigen-binding fragment are each composed of two or more segments of amino acid sequence from one or more other antibodies or antigen-binding fragments, whereby the segments are neither whole CDRs nor framework regions.

2 - 36 . (canceled)

37 . An antibody or antigen-binding fragment comprising a composite antibody variable region, the antibody variable region being derived from multiple segments of amino acid sequence of 2 to 31 amino acids long from other antibodies or antigen-binding fragments, wherein the multiple segments are neither whole CDRs nor whole framework regions, and wherein each segment of the multiple segments that form the antibody variable region is no longer contiguous with the surrounding sequences in the antibody or antigen-binding fragment from which the segment was derived.

38 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment is a human antibody or antigen-binding fragment.

39 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment is an antibody.

40 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment is an antigen-binding fragment.

41 . The antigen-binding fragment of claim 40 , wherein the antigen-binding fragment is selected from Fv's, Fab's, Fab2's, SCA's, single domain antibodies, and multimeric derivatives of each of these.

42 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment is devoid of helper T cell epitopes.

43 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment comprises one or more regulatory T cell epitopes which suppress immune reactions.

44 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment binds to human HER2.

45 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment binds to human Lewis Y antigen.

46 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment binds to human IgE.

47 . The antibody or antigen-binding fragment of claim 37 , wherein the antibody or antigen-binding fragment binds to human TNF-alpha.

48 . A pharmaceutical composition comprising an antibody or antigen-binding fragment of claim 37 .

49 . The pharmaceutical composition of claim 48 , wherein the antibody or antigen-binding fragment binds to human HER2.

50 . The pharmaceutical composition of claim 48 , wherein the antibody or antigen-binding fragment binds to human Lewis Y antigen.

51 . The pharmaceutical composition of claim 48 , wherein the antibody or antigen-binding fragment binds to human IgE.

52 . The pharmaceutical composition of claim 48 , wherein the antibody or antigen-binding fragment binds to human TNF-alpha.

53 . A method of producing an antibody or antigen-binding fragment comprising:

expressing a gene encoding an antibody or antigen-binding fragment of claim 1 ; and

recovering the expressed antibody or antigen-binding fragment.

54 . The method of claim 53 , wherein the antibody or antigen-binding fragment is a human antibody or antigen-binding fragment.

55 . The method of claim 53 , wherein the antibody or antigen-binding fragment is an antibody.

56 . The method of claim 53 , wherein the antibody or antigen-binding fragment is an antigen-binding fragment.

57 . The method of claim 56 , wherein the antigen-binding fragment is selected from Fv's, Fab's, Fab2's SCA's, single domain antibodies, and multimeric derivatives of each of these.

58 . The method of claim 53 , wherein the antibody or antigen-binding fragment is devoid of helper T cell epitopes.

59 . The method of claim 53 , wherein the antibody or antigen-binding fragment comprises one or more regulatory T cell epitopes which suppress immune reactions.

60 . The method of claim 53 , wherein the antibody or antigen-binding fragment binds to human HER2.

61 . The method of claim 53 , wherein the antibody or antigen-binding fragment binds to human Lewis Y antigen.

62 . The method of claim 53 , wherein the antibody or antigen-binding fragment binds to human IgE.

63 . The method of claim 53 , wherein the antibody or antigen-binding fragment binds to human TNF-alpha.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2017
From: JONES, TIMOTHY DAVID; BAKER, MATTHEW PAUL
To: ANTITOPE LIMITED
Reel/Frame 043422/0225 →